Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kaneka Nutrients","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results Evaluating The Effect Of Kaneka Nutrients' Ubiquinol On Endothelial Function Published In Nutrients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"McGill University","sponsor":"Clarus","pharmaFlowCategory":"D","amount":"$40.8 million","upfrontCash":"$0.4 million","newsHeadline":"Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"BPGbio","sponsor":"Debra of America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BPGbio Announces Expanded Partnership with debra of America for BPM 31510 for Epidermolysis Bullosa Phase II\/III Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi to Acquire Qunol\u00ae, a Fast-Growing U.S. Brand in the Healthy Aging Segment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Completes Acquisition of Qunol\u00ae","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Coenzyme Q10

    Menu

    Coenzyme Q10

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Qunol

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sanofi Completes Acquisition of Qunol®

              Details:

              Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.

              Lead Product(s): Coenzyme Q10,Vitamin E

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Qunol CoQ10

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition September 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qunol

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sanofi to Acquire Qunol®, a Fast-Growing U.S. Brand in the Healthy Aging Segment

              Details:

              Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.

              Lead Product(s): Coenzyme Q10,Vitamin E

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Qunol CoQ10

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition July 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BPGbio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BPGbio Announces Expanded Partnership with debra of America for BPM 31510 for Epidermolysis Bullosa Phase II/III Trial

              Details:

              The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.

              Lead Product(s): Coenzyme Q10

              Therapeutic Area: Rare Diseases and Disorders Product Name: BPM31510

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Debra of America

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              McGill University

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With ...

              Details:

              Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).

              Lead Product(s): Coenzyme Q10,Caspofungin

              Therapeutic Area: Genetic Disease Product Name: Ubiquinone

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Clarus

              Deal Size: $40.8 million Upfront Cash: $0.4 million

              Deal Type: Licensing Agreement September 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kaneka Nutrients

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Results Evaluating The Effect Of Kaneka Nutrients' Ubiquinol On Endothelial Function Published In Nutrients

              Details:

              Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day; Ubiquinol 100 mg/day; placebo).

              Lead Product(s): Coenzyme Q10

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ubiquinol

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Basic Nutrition Coenzyme Q10
              Temad- We think of world-class quality.
              Close
              4
              Post Enquiry
              POST ENQUIRY